Objective: To study the effect of metabolic syndrome (MetSyn) on cardiovascular outcomes after percutaneous coronary intervention (PCI) with bare-metal stents (BMS). Background: The constellation of dyslipidemia, impaired fasting glucose, high blood pressure and abdominal obesity is recognized as MetSyn. MetSyn increases mortality after coronary artery bypass grafting. The influence of MetSyn on outcomes after PCI is less well studied. Results: The influence of MetSyn on major adverse cardiac events (MACE) in PCI patients with BMS was studied. MetSyn factors showed a significant relationship to MACE. When compared with no MetSyn factors, the adjusted hazard ratio for one and four MetSyn factors was 1.24 (95% CI: 0.85-1.81) and 1.65 (1.11-2.45), respectively. Cox regression identified MetSyn as a significant predictor of MACE. Conclusion: MetSyn increases MACE risk in PCI patients with BMS. The risk is worse with increasing number of MetSyn components. Aggressive treatment of patients with MetSyn after PCI is warranted.
- bare-metal stents
- drug-eluting stents
- major adverse cardiac events
- metabolic syndrome
- percutaneous coronary intervention